

**LIST OF ART CITED BY APPLICANT**

ATTY. DOCKET: 17549 (AP)	SERIAL NO.: 10/617,468
APPLICANT: P. M. HUGHES, ET AL.	TITLE: DELIVERY OF AN ACTIVE DRUG TO THE POSTERIOR PART OF THE EYE VIA SUBCONJUNCTIVAL OR PERIOcular DELIVERY OF A PRODRUG
FILING DATE: JULY 10, 2003	GROUP:

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (If applicabl )
<i>74B</i>	AA	2002/0049255A1	4/25/02	Gamache, et al.			08/13/01
<i>74B</i>	AB	2003/0018044A1	1/23/03	Peyman			9/19/02
<i>74B</i>	AC	4,997,652	3/5/91	Wong			
<i>74B</i>	AD	4,853,224	8/1/89	Wong			
<i>74B</i>	AE	5,164,188	11/17/92	Wong			
<i>74B</i>	AF	5,443,505	8/22/95	Wong, et al.			
<i>74B</i>	AG	5,476,511	12/19/95	Gwon, et al.			
<i>74B</i>	AH	5,632,984	5/27/97	Wong, et al.			
<i>74B</i>	AI	5,766,242	6/16/98	Wong, et al.			
<i>74B</i>	AJ	5,780,647	7/14/98	Vuligonda et al.			
<i>74B</i>	AK	5,824,072	10/20/98	Wong			
<i>74B</i>	AL	6,060,463	5/9/00	Freeman			
<i>74B</i>	AM	6,378,526 B1	4/30/02	Bowman, et al.			
<i>74B</i>	AN	6,397,849	6/4/02	Bowman, et al.			
<i>74B</i>	AO	6,416,777 B1	7/9/02	Yaacobi			
<i>74B</i>	AP	6,489,335 B2	12/3/02	Peyman			

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/n )
<i>74B</i>	BA	WO 91/19482	12/26/91	PCT			
<i>74B</i>	BB	WO 93/06856	4/15/93	PCT			
<i>74B</i>	BC	WO 95/26734	10/12/95	PCT			
<i>74B</i>	BD	WO 00/07565	2/17/00	PCT			
<i>74B</i>	BE	WO 02/41910 A2	5/30/02	PCT			

**OTHER ART**


(Including Author, Title, Date, Pertinent Pages, etc.)

<i>74B</i>	CA	Alminger, T.B., et al., (Pyridinylmethyl)Chemical Abstracts, Vol. 110, 1989, pg. 692, 57664
<i>74B</i>	CB	Baker, L., et al., Abstract Pars Plana Jet Injection of Ganciclovir, IOVS, 1990;31(4):306
<i>74B</i>	CC	Ball, S., Concentration change and activity of fluorouracil in the external segment of the eye after subconjunctival injection, Arch Ophthalmol, Vol. 107, September 1989, pgs 1276-1277
<i>74B</i>	CD	Bundgaard, H., Design of Prodrugs: Bioreversible derivatives for various functional groups and chemical entities, Design of Prodrugs (Bundgaard, H., ed.) 1985 Elsevier Science Publishers B.V., Biomedical Division, Chp. 1, pg. 1-92.

EXAMINER *74B*

DATE CONSIDERED 6/29/07

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF ART CITED BY APPLICANT


ATTY. DOCKET: 17549 (AP)	SERIAL NO.: 10/617,468
APPLICANT: P. M. HUGHES, ET AL.	TITLE: DELIVERY OF AN ACTIVE DRUG TO THE POSTERIOR PART OF THE EYE VIA SUBCONJUNCTIVAL OR PERIOcular DELIVERY OF A PRODRUG
FILING DATE: JULY 10, 2003	GROUP:

752	CE	Bundgaard, H., et al., Prodrugs as drug delivery systems XIX. Bioreversible derivatization of aromatic amines by formation of N-mannich bases with succinimide, <i>International Journal of Pharmaceutics</i> , 8(1981) 183-192
753	CF	Bundgaard, H., et al., Hydrolysis of N-Mannich bases and its consequences for the biological testing of such agents, <i>Int. J. Pharm.</i> 1981 9(1), 7-16
754	CG	Bundgaard, H., et al., Phenyl carbamates of amino acids as prodrugs forms for protecting phenols against first-pass metabolism, <i>Int. J. Pharm.</i> 81 (1992) 253-261
755	CH	Bundgaard, H., et al., Pro drugs as drug delivery systems. X.imides, urea derivatives, amines and other NH-acidic compounds. <i>Arch Pharm Chemi, Sci. Ed.</i> , 1980 8(2) 29-52
756	CI	Bundgaard, et al., A novel solution-stable, water-soluble prodrug type for drugs containing a hydroxyl or an NH-acidic group, <i>J. of Medicinal Chemistry</i> , Vo. 32, No. 12, Dec. 1989, pg. 2503-2507
757	CJ	Bundgaard, H., et al., Prodrugs as drug delivery systems. 43. O-acyloxymethyl salicylamide N-mannich bases as double prodrug forms for amines, <i>Int. J. of Pharm.</i> , 29 (1986) 19-28
758	CK	Bundgaard, H., et al., Hydrolysis of N-( $\alpha$ -hydroxyalkyl) amide derivatives: implications for the design of N-acyloxyalkyl-type prodrugs, <i>Intl. Journal of Pharm</i> 22, (1984) 45-56
759	CL	Buur, A, et al., <i>Acta Pharm Nord</i> , 1991 3(1) 51-6
760	CM	<del>Cheng, Y. et al., Relationship between the inhibition constant (<math>K_i</math>) and the concentration of inhibitor which causes 50 per center inhibition (<math>I_{50}</math>) of an enzymatic reaction, <i>Biochemical Pharm.</i>, Vol 22, pp. 3099-3108</del>
761	CN	Chiang, C., et al., In vitro and in vivo evaluation of an ocular delivery system of 5-fluorouracil microspheres, <i>J. of Ocular Pharm and Therapeutics</i> , Vol. 17, No. 6, 2001; pgs. 545-553
762	CO	Joshi, A., Microparticles for Ophthalmic Drug Delivery, <i>Journal of Ocular Pharmacology</i> , Vol. 10, No. 1, 1994, pp. 29-45
763	CP	Einmahl, S. ("A Novel Route of Ocular Drug Delivery: Suprachoroidal Injections Of A Sustained-Release System", <i>Proceed. Int'l. Symp. Rel. Bioact. Mater.</i> , 28, (2001), pp. 293-294
764	CQ	Einmahl, S., et al., Abstract, Evaluation of a new biomaterial injected in the suprachoroidal space of the rabbit eye, <i>IOVS</i> , 2001;42(4) 1 pg
765	CR	Giordano, G.G., et al., Sustained delivery of retinoic acid from microspheres of biodegradable polymer in PVR, <i>Investigative Ophthalmology &amp; Visual Science</i> , Aug 1993;34(9), pgs 2743-2751.
766	CS	Hansen, K.T., et al., Carbamate ester prodrugs of dopaminergic compounds: synthesis, stability and bioconversion, <i>J. Pharm Sc.</i> 1991, 80(8) 793-798
767	CT	Herrero-Vanrell, R., et al., Biodegradable PLGA microspheres loaded with ganciclovir for intraocular administration. Encapsulation technique, in vitro release profiles and sterilization process, <i>Pharmaceutical Research</i> , Vol. 17, No. 10, 2000, pgs. 1323-1328
768	CU	Jensen, E., et al., N-substituted (aminomethyl) benzoate 21-esters of corticosteroids as water-soluble, solution-stable and biolabile prodrugs., <i>Acta Pharm Nord.</i> , 1992 4(1) 35042

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



**ART CITED BY APPLICANT**

ATTY. DOCKET: 17549 (AP)	SERIAL NO.: 10/617,468
APPLICANT: P. M. HUGHES, ET AL.	TITLE: DELIVERY OF AN ACTIVE DRUG TO THE POSTERIOR PART OF THE EYE VIA SUBCONJUNCTIVAL OR PERIOcular DELIVERY OF A PRODRUG
FILING DATE: JULY 10, 2003	GROUP:

TEB	CV	Joshi, A., Microparticulates for ophthalmic drug delivery, <i>J. of Ocular Pharmacology</i> , Vol. 10, No. 1, 1994
TEB	CW	Kawase, K., et al., Mitomycin concentration in rabbit and human ocular tissues after topical administration, <i>Ophthalmology</i> , Vol. 99, No. 2, February 1992, pgs. 203-207
TEB	CX	Kondo, et al., Concentration change of fluorouracil in the external segment of the eye after subconjunctival injection, <i>Arch Ophthalmol</i> 1988;106:1718-1721
TEB	CY	Maritera, T., et al., Microspheres of biodegradable polymers as a drug delivery system in the vitreous, <i>Invest Ophthalmol Vis Sci</i> , 32:1785-1790, 1991
TEB	CZ	Nagy, B., et al., Study on subconjunctival application of capsulated tobramycin, <i>Ann. Immunol. hung</i> , 25:355-363; 1985
TEB	CAA	Pinilla, I., et al., Subconjunctival injection of low doses of mitomycin C: effects on fibroblast proliferation, <i>Ophthalmologica</i> , 1998;212:306-309
748	CBB	Thomsen, K.F., et al., Evaluation of phenyl carbamates of ethyl diamines as cyclization-activated prodrug forms for protecting phenols against first-pass metabolism, <i>Int. J. Pharm.</i> 1994, 112(2) 143-52

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17549 (AP)	SERIAL NO.: 10/617,468
APPLICANT: P. M. HUGHES, ET AL.	TITLE: DELIVERY OF AN ACTIVE DRUG TO THE POSTERIOR PART OF THE EYE VIA SUBCONJUNCTIVAL OR PERIOcular DELIVERY OF A PRODRUG
FILING DATE: JULY 10, 2003	GROUP: 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
728	AA	5,384,333	01/24/1995	DAVIS et al.	514	772.3	
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
728	BA	WO 96/38133	12/05/1996	PCT	A61K	9/14	Y
728	BB	WO 00/03660	07/16/1999	PCT	A61K	2/02	Y
728	BC	WO 02/087586	04/26/2002	PCT	A61K	31/513	Y
728	BD						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

728	CA	Khoobehi, Bahram, et al., <i>Clearance of Fluorescein Incorporated Into Microspheres From the Cornea and Aqueous After Subconjunctival Injection</i> , Ophthalmic Surgery, December 1990, Vol. 21, No. 12, pp. 840-844
728	CB	Kompella, Uday, et al., <i>Subconjunctival Nano- and Microparticles Sustain Retinal Delivery of Budesonide, a Corticosteroid Capable of Inhibiting VEGF Expression</i> , IOVS, March 2003, Vol. 44, No. 3, pp. 1192-1200
728	CC	Lallemant, F., et al., <i>Cyclosporine A delivery to the eye: A pharmaceutical challenge</i> , Eur. J. Pharm & Biopharm, 56 (2003), pp. 307-318
728	CD	de Rojas-Silva, M.-V., et al., <i>Efficacy of subconjunctival cyclosporine-containing microspheres on keratoplasty rejection in the rabbit</i> , Graefe's Arch Clin Exp Ophthalmol (1999) 237, pp. 840-847
728	CE	Saishin, Y., et al., <i>Periocular Injection of Microspheres Containing PKC412 Inhibits Choroidal Neovascularization in a Porcine Model</i> , IOVS, November 2003, Vol. 44, No. 11, pp. 4989-4993
	CF	
	CG	
	CH	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.